Anthropic Launches Internal Drug Discovery Programs for Neglected Diseases Alongside Claude Science

What Happened

Anthropic announced internal preclinical drug discovery programs targeting neglected diseases — conditions where biology is well understood but pharmaceutical economics are unattractive. This expands on the ~$400M Coefficient Bio acquisition (April 2026) and Claude Science launch (June 30, 2026).\n\n## Context and Impact
CEO Dario Amodei aims to use AI to compress life sciences R&D cycles by 10x. Claude Science connects 60+ scientific tools and databases including PubMed and Jupyter, capable of running single-cell RNA sequencing and CRISPR design autonomously. Strategic intent: hands-on drug development provides feedback for better AI products, attracting biopharma customers.\n\n## Details

• Coefficient Bio (Samuel Stanton, Nathan Frey) — both previously from Genentech's Prescient Design
• Claude Science available in beta for Pro, Max, Team, and Enterprise plans
• First demo: AI independently identified potential treatments for phenylketonuria
• John Jumper (led AlphaFold team at Google DeepMind) now at Anthropic